An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis

An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)

This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment. Data will be collected from patients receiving once monthly Mircera according to standard of care and local labelling during 12 months of treatment.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Stage IV chronic kidney disease, on haemodialysis
• Chronic renal anemia, on maintenance ESA treatment
• Hemoglobin concentration between 10.0 an 12 g/dL
• Continuous maintenance epoetin therapy with the same dosing interval during the previous month

Exclusion Criteria:

• Contraindications to ESA treatment (e.g. hypersensitivity, non-controlled hypertension)
• Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
• Anemia due to hemolysis, pure red cell aplasia